Streetbeat News

Stock Prices

ALPMF

ALPMY

MRK

SGEN

Seagen Inc and Astellas Pharma Inc released positive results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck & Co Inc's Keytruda versus chemotherapy in bladder cancer. The trial met its dual primary endpoints of overall survival and progression-free survival compared to chemotherapy. The results are expected to confirm the current U.S. accelerated approval of Keytruda in combination with enfortumab vedotin as first-line treatment for urothelial carcinoma. Seagen's shares are up 3.54% at $213.69.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 3:05 pm

FSLR

Over the past 3 months, 23 analysts have published their opinion on First Solar (NASDAQ:FSLR) stock. The company has an average price target of $236.91, an increase of 3.79% from the previous average price target of $228.26. The ratings are derived from company conference calls, financial statements, and insider conversations.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:01 pm

MIDD

Five analysts have given bullish ratings for Middleby (NASDAQ:MIDD) in the last quarter, with an average 12-month price target of $167.0, a decrease of 1.18% from the previous average price target of $169.00.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:01 pm

AXP

American Express (NYSE:AXP) has outperformed the market over the past 15 years, producing an average annual return of 10.9%. If an investor had bought $100 of AXP stock 15 years ago, it would be worth $389.14 today. The company currently has a market capitalization of $113.20 billion.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

JAMF

Over the past 3 months, 8 analysts have published their opinion on Jamf Holding (NASDAQ:JAMF) stock. The average price target for the stock is $29.38, with a high of $35.00 and a low of $22.00. This average price target has increased by 24.12% over the past month.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

TRV

Travelers Companies (NYSE:TRV) has outperformed the market over the past 15 years, producing an average annual return of 10.83%. If an investor had bought $1000 of TRV stock 15 years ago, it would be worth $3,826.14 today.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

ZION

Zions Bancorp (NASDAQ:ZION) has received mostly positive ratings from analysts in the last quarter, with 3 bullish, 2 somewhat bullish, and 8 indifferent ratings. The average 12-month price target for ZION has increased by 12.94% to $36.23.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

GSK

GSK Inc.'s stock has increased by 8.51% over the past month and by 30.92% over the past year. Despite this, its price-to-earnings (P/E) ratio is lower than the aggregate P/E of the pharmaceuticals industry, which could indicate that the stock is undervalued or that shareholders do not expect it to perform better in the future.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

XPO

In the last quarter, XPO Logistics (NYSE:XPO) has received mostly bullish ratings from 25 analysts, with an average price target of $71.92, indicating an upside from the current price of $69.315. This average price target has increased by 23.02% from the previous average of $58.46.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

WFC

Wells Fargo & Co (NYSE:WFC) shares are trading lower by 1.6% amid overall market weakness and concerns about future rate hikes following the FOMC statement and lower-than-expected initial jobless claims data. Higher interest rates can lead to higher funding costs for banks, squeezing their net interest income and potentially reducing profitability. The Federal Reserve maintained the federal funds rate within the 5.25% to 5.5% range at its September meeting.

Portfolio Pulse from Henry Khederian

September 22, 2023 | 2:58 pm